

Supplementary Material to

## **Evaluation of the Potential of Cobalamin Derivatives Bearing Ru(II) Polypyridyl Complexes as Photosensitisers for Photodynamic Therapy**

Marta Jakubaszek,<sup>1,2,#</sup> Jeremie Rossier,<sup>3,#</sup> Johannes Karges,<sup>1,#</sup> Joachim Delasoie,<sup>3,#</sup> Bruno

Goud,<sup>2</sup> Gilles Gasser<sup>1,\*</sup> and Fabio Zobi<sup>3,\*</sup>

<sup>1</sup> Chimie ParisTech, PSL University, CNRS, Institute of Chemistry for Life and Health Sciences, Laboratory for Inorganic Chemical Biology, F-75005 Paris.

<sup>2</sup> Institut Curie, PSL University, CNRS UMR 144, Paris, France.

<sup>3</sup> Chemistry Department, University of Fribourg, CH-1700 Fribourg.


\*Correspondence: [gilles.gasser@chimieparistech.psl.eu](mailto:gilles.gasser@chimieparistech.psl.eu); [www.gassergroup.com](http://www.gassergroup.com);  
[fabio.zobi@unifr.ch](mailto:fabio.zobi@unifr.ch); [www.fabiozobi.wixsite.com/zobigroup](http://www.fabiozobi.wixsite.com/zobigroup)

# these authors have contributed equally to the work.

## Table of Content:

### Supplementary Figures


<b>Figure S1.</b> 500 MHz $^1\text{H}$ -NMR of compound <b>B<sub>12</sub>-2</b>	S2
<b>Figure S2.</b> Normalized UV-Vis of compounds <b>2</b> , <b>B<sub>12</sub>-2</b> and of cyanocobalamin	S2
<b>Figure S3.</b> HPLC chromatogram of compound <b>B<sub>12</sub>-2</b>	S3
<b>Figure S4.</b> HR-ESI-MS of compound <b>B<sub>12</sub>-2</b>	S4
<b>Figure S5.</b> Cytotoxicity of compound <b>2</b> in HeLa cell line	S5
<b>Figure S6.</b> Cytotoxicity of complex <b>2</b> in RPE-1 cell line	S6
<b>Figure S7.</b> Cytotoxicity of complex <b>B<sub>12</sub>-2</b> in HeLa cell line	S7
<b>Figure S8.</b> Cytotoxicity of complex <b>B<sub>12</sub>-2</b> in RPE-1 cell line.	S8
<b>Figure S9.</b> Cytotoxicity of compound <b>1</b> in HeLa cell line	S9
<b>Figure S10.</b> Cytotoxicity of complex <b>1</b> in RPE-1 cell line	S10
<b>Figure S11.</b> Cytotoxicity of complex <b>B<sub>12</sub>-1</b> in HeLa cell line	S11
<b>Figure S12.</b> Cytotoxicity of complex <b>B<sub>12</sub>-1</b> in RPE-1 cell line.	S12
<b>Figure S13.</b> Cellular localisation of the complexes.	S13




**Figure S1.** 500 MHz  $^1\text{H}$ -NMR of compound B<sub>12</sub>-2 (in D<sub>2</sub>O, \* = solvent residual peak).

**$^1\text{H}$  NMR** (500 MHz, MeOD- $[\text{d}_4]$ ) peak assignment (see scheme on page S4):  $\delta$  = 8.53 (t,  $J$  = 9.5 Hz, 4H, HC-13/22/31/40L), 8.25 (t,  $J$  = 9.37 Hz, 1H, HC-9L), 8.09-7.99 (m, 5H, HC-12L, HC-16/19/34/37L), 7.85-7.69 (m, 6H, HC-7L, HC-10L, HC-15/20/33/38L), 7.54 (dd,  $J$  = 6.0, 2.37 Hz, 1H, HC-5L), 7.40-7.32 (m, 5H, HC-11L, HC-14/21/32/39L), 7.29 (s, 1H, HC-7N), 7.14 (s, 1H, HC-2N), 6.82-6.76 (m, 1H, HC-4L), 6.50 (s, 1H, HC-4N), 6.37 (d,  $J$  = 3.2 Hz, 1H, HC-1R), 6.05 (d,  $J$  = 3.8 Hz, 1H, HC-10), 4.38-4.23 (m, 2H, HC-3R, HC-3), 4.13-4.07 (m, 1H, HC-19), 3.95 (dd,  $J$  = 13.0, 2.45 Hz, 1H, HC-176), 3.78 (dd,  $J$  = 13.0, 4.0 Hz, 2H, HC-2R, HC-4R), 3.62 (d,  $J$  = 14.3 Hz, 1H, H<sub>b</sub>C-5R), 3.43-3.35 (m, 2H, H<sub>a</sub>C-5R, H<sub>b</sub>C-175), 3.32-3.25 (m, 2H, HC-8, HC-13), 2.99 (dd,  $J$  = 9.0, 5.3 Hz, 2H, H<sub>b</sub>C-171, H<sub>b</sub>C-172), 2.79-2.32 (m, 16H, H<sub>a</sub>C-175, HC-18, H<sub>3</sub>C-51, H<sub>3</sub>C-151, H<sub>a</sub>C-181, HC-21, H<sub>a</sub>C-132, H<sub>b</sub>C-71, H<sub>b</sub>C-132, H<sub>b</sub>C-71, H<sub>a</sub>C-82), 2.27 (s, 6H, H<sub>3</sub>C-10N, H<sub>3</sub>C-11N), 2.14 (t,  $J$  = 12.0, 1H, H<sub>a</sub>C-171), 2.09-1.93 (m, 7H, H<sub>a</sub>C-181, H<sub>b</sub>C-131, H<sub>a</sub>C-71, H<sub>b</sub>C-81, H<sub>b</sub>C-31, H<sub>a</sub>C-31, H<sub>a</sub>C-131), 1.89-1.77 (m, 5H, H<sub>3</sub>C-7A, H<sub>a</sub>C-172, H<sub>b</sub>C-82), 1.45 (d,  $J$  = 4.2 Hz, 3H, H<sub>3</sub>C-12A), 1.40 (d,  $J$  = 3.4 Hz, 3H, H<sub>3</sub>C-2A), 1.34 (s, 3H, H<sub>3</sub>C-17B), 1.27 (d,  $J$  = 6.3 Hz, 3H, H<sub>3</sub>C-177), 1.18 (t, 1H, H<sub>a</sub>C-81), 1.15 (s, 3H, H<sub>3</sub>C-12B), 1.13-1.02 (m, 2H, H<sub>2</sub>C-32), 0.52 (s, 3H, H<sub>3</sub>C-1A) ppm






**Figure S2.** Normalized UV-Vis of compounds **2**, **B<sub>12</sub>-2** and of cyanocobalamin (CN-Cbl) in methanol.




**Figure S3.** HPLC chromatogram of compound **B<sub>12</sub>-2**.




**Figure S4.** HR-ESI-MS of compound B<sub>12</sub>-2. Insert shows isotope pattern of 960.83153 peak.

### Cytotoxicity of Complex 2 in HeLa -1<sup>st</sup> repeat



### Cytotoxicity of Complex 2 in HeLa- 2<sup>nd</sup> repeat



### Cytotoxicity of Complex 2 in HeLa- 3<sup>rd</sup> repeat






Figure S5. Cytotoxicity of complex 2 in the HeLa cell line.

### Cytotoxicity of complex 2 in RPE-1 -1<sup>st</sup> repeat



### Cytotoxicity of complex 2 in RPE-1 -2<sup>nd</sup> repeat



### Cytotoxicity of complex 2 in RPE-1 -3<sup>rd</sup> repeat






Figure S6. Cytotoxicity of complex 2 in the RPE-1 cell line.




### Cytotoxicity of complex B<sub>12</sub>-2 in HeLa -1<sup>st</sup> repeat



### Cytotoxicity of complex B<sub>12</sub>-2 in HeLa -2<sup>nd</sup> repeat




### Cytotoxicity of complex B<sub>12</sub>-2 in HeLa -3<sup>rd</sup> repeat




**Figure S7.** Cytotoxicity of complex B<sub>12</sub>-2 in the HeLa cell line.


### Cytotoxicity of complex B<sub>12</sub>-2 in RPE-1 -1<sup>st</sup> repeat



### Cytotoxicity of complex B<sub>12</sub>-2 in RPE-1 -2<sup>nd</sup> repeat




### Cytotoxicity of complex B<sub>12</sub>-2 in RPE-1 -3<sup>rd</sup> repeat




**Figure S8.** Cytotoxicity of complex B<sub>12</sub>-2 in the RPE-1 cell line.

### Cytotoxicity of complex 1 in HeLa -1<sup>st</sup> repeat



### Cytotoxicity of Complex 1 in HeLa-2<sup>nd</sup> repeat



### Cytotoxicity of Complex 1 in HeLa-3<sup>rd</sup> repeat






Figure S9. Cytotoxicity of complex 1 in the HeLa cell line.


### Cytotoxicity of complex 1 in RPE-1 -1<sup>st</sup> repeat



### Cytotoxicity of complex 1 in RPE-1 -2<sup>nd</sup> repeat




### Cytotoxicity of complex in RPE-1 -3<sup>rd</sup> repeat




**Figure S10.** Cytotoxicity of complex 1 in the RPE-1 cell line.


### Cytotoxicity of Complex B<sub>12</sub>-1 in HeLa -1<sup>st</sup> repeat



### Cytotoxicity of Complex B<sub>12</sub>-1 in HeLa-2<sup>nd</sup> repeat




### Cytotoxicity of Complex B<sub>12</sub>-1 in HeLa-3<sup>rd</sup> repeat




**Figure S11.** Cytotoxicity of complex B<sub>12</sub>-1 in the HeLa cell line.


### Cytotoxicity of complex B<sub>12</sub>-1 in RPE-1 -1<sup>st</sup> repeat




### Cytotoxicity of complex B<sub>12</sub>-1 in RPE-1 -2<sup>nd</sup> repeat



### Cytotoxicity of complex B<sub>12</sub>-1 in RPE-1 -3<sup>rd</sup> repeat



**Figure S12.** Cytotoxicity of complex B<sub>12</sub>-1 in the RPE-1 cell line.



**Figure S13.** Cellular localisation of the complexes in HeLa cell line. Cells were treated with the compounds (IC<sub>50</sub> concentration in the dark) for 2 h and co-stained with NucBlue and Mitotracker Green FM. Compounds were then removed, cells were fixed and visualised by confocal microscopy.